Silverback Therapeutics, Inc.

Industry

  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
    • Drug Delivery
      • Site Specific

Other Names/Subsidiaries

  • ARS Pharmaceuticals, Inc.
See more in Biomedtracker

Latest on Silverback Therapeutics, Inc.

Scrip

Finance Watch: Another Bevy Of VC Mega-Rounds, Including $175m For Capstan

 
• By Mandy Jackson

Capstan Therapeutics Inc. and Engrail Therapeutics are among the latest companies to raise venture capital mega-rounds of $100m or more as the deluge of large private financings early in 2024 coinc

Scrip

Deal Watch: Japan’s SNBL To Re-Absorb US Spinout Satsuma

 
• By Joseph Haas, Lisa Takagi, and Dexter Jie Yan

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. SNBL To Pay 28% Premium To Re-Acquire S

Scrip

Capstan Launches, Backed By Big Names And Big Pharma, To Pioneer In Vivo Cell Therapies

 
• By Jessica Merrill

Capstan Therapeutics is advancing first-in-class in vivo chimeric antigen receptor (CAR) therapies that could have applicability across a wide range of therapeutic areas from a high-profile team of

Scrip

Deal Watch: Cidara Licenses US Rights To Antifungal Under FDA Review To Melinta

 
• By Joseph Haas and Lisa Takagi

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Cidara Hopes For Early 2023 Approval Of